Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.46%
#2 Ontology Gas Ontology Gas +131.75%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +35.55%
#5 BOOK OF MEME BOOK OF MEME +31.03%
#6 Ontology Ontology +30.60%
#7 Neiro Neiro +30.07%
#8 Collect on Fanable Collect on Fanable +28.80%
#9 Unit Pump Unit Pump +28.63%
#10 Pump.fun Pump.fun +28.63%
Coin of the day
Pleasing Gold Pleasing Gold
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
LianBio LianBio

LianBio

LIAN
Clasificación en acciones #25844
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Precio por acción
$0.42275
Última sincronización: 2025-07-14
Capitalización bursátil
$45.81M
Cambio (1 día)
-0.89%
Cambio (1 año)
0.00%
País
US
Comercio LianBio (LIAN)

Categoría

Healthcare
Historial del precio de la acción de LianBio (LIAN)
Precio más alto de cierre: $0.42 el 2025-07-01

Precio más bajo de cierre: $14.58 el 2021-11-01
Historial del precio de la acción de LianBio desde 2021 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2025 44.04%
2024 -93.17%
2023 184.09%
2022 -82.11%
2021 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $539.14 36.71%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.04K 56.86%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $120.74 -14.98%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $761.87 7.04%
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $130.43 385.07%
US